Selected article for: "age group and RSV incidence"
Author: Freitas, André Ricardo Ribas; Donalisio, Maria Rita
Title: Respiratory syncytial virus seasonality in Brazil: implications for the immunisation policy for at-risk populations
  • Document date: 2016_5_23
    • ID: 0ss52vfd_7
    Snippet: Despite improvements in RSV infection supportive care, no vaccine is available (Borchers et al. 2013 , Haynes 2013 . Monoclonal antibody prophylaxis has been shown to be effective in reducing the number of hospitalisations in children under 2 years of age with risk factors for aggravation (IMpact-RSV Study Group 1998). However, the high cost of prophylaxis has limited its usage, especially in developing countries. Current protocols recommend a ma.....
    Document: Despite improvements in RSV infection supportive care, no vaccine is available (Borchers et al. 2013 , Haynes 2013 . Monoclonal antibody prophylaxis has been shown to be effective in reducing the number of hospitalisations in children under 2 years of age with risk factors for aggravation (IMpact-RSV Study Group 1998). However, the high cost of prophylaxis has limited its usage, especially in developing countries. Current protocols recommend a maximum of five consecutive monthly doses of palivizumab per year during the period of greatest incidence of RSV (CID 2009 , SBP 2011 .

    Search related documents:
    Co phrase search for related documents
    • antibody prophylaxis and high cost: 1
    • antibody prophylaxis and monoclonal antibody prophylaxis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • antibody prophylaxis and RSV infection: 1, 2, 3
    • current protocol and risk factor: 1, 2, 3, 4
    • current protocol and RSV infection: 1
    • current protocol and supportive care: 1, 2, 3
    • high cost and hospitalisation number: 1
    • high cost and monoclonal antibody prophylaxis: 1
    • high cost and prophylaxis high cost: 1, 2
    • high cost and risk factor: 1
    • high cost and RSV infection: 1, 2, 3, 4, 5, 6, 7
    • high cost and supportive care: 1, 2
    • hospitalisation number and prophylaxis high cost: 1
    • hospitalisation number and RSV infection: 1, 2
    • monoclonal antibody prophylaxis and RSV infection: 1, 2, 3
    • prophylaxis high cost and RSV infection: 1
    • risk factor and RSV infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • risk factor and supportive care: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • RSV infection and supportive care: 1, 2, 3, 4